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Abstract
 There is a need to prevent and treat infection in newborns. OneBackground:
approach is administration of antimicrobial proteins and peptides (APPs) such
as LL-37, a membrane-active cathelicidin antimicrobial peptide, and
mannose-binding lectin (MBL), a pattern-recognition protein that binds to
microbial surface polysaccharides resulting in opsonization and complement
activation. Low plasma/serum levels of LL-37 and of MBL have been correlated
with infection and exogenous administration of these agents may enhance host
defense.
 The antimicrobial activity of LL-37 (15 µg/ml) or rMBL (0.5, 2 and 10Methods:
µg/ml) was tested in hirudin-anticoagulated preterm and term human cord
blood (N = 12–14) against   (SA) USA 300 (2x10Staphylococcus aureus
CFU/ml),   (SE) 1457 (2x10 CFU/ml) and Staphylococcus epidermis Candida
 (CA) SC5314 (1x10 CFU/ml). After incubation (1, 45, or 180 min),albicans
CFUs were enumerated by plating blood onto agar plates. Supernatants were
collected for measurement of MBL via ELISA.
 Preterm cord blood demonstrated impaired endogenous killingResults:
capacity against SA and SE compared to term blood. Addition of LL-37 strongly
enhanced antimicrobial/antifungal activity vs SA, SE and CA in term blood and
SE and CA in preterm blood. By contrast, rMBL showed modest fungistatic
activity vs CA in a sub-analysis of term newborns with high basal MBL levels.
Baseline MBL levels varied within preterm and term cohorts with no correlation
to gestational age. In summary, exogenous LL-37 demonstrated significant
antimicrobial activity against SA, SE and CA in term and SE and CA in preterm
human blood tested  . rMBL demonstrated modest antifungal activity inin vitro
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 human blood tested  . rMBL demonstrated modest antifungal activity inin vitro
term cord blood of individuals with high baseline MBL levels.
 To the extent that our   results predict the effects of APPs Conclusions: in vitro
, development of APPs for prevention and treatment of infection shouldin vivo
take into account host age as well as the target pathogen.
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Introduction
Neonatal sepsis is a major contributor to neonatal morbidity and 
mortality; consequently, efforts to ease the burden of this disease 
are crucial1. Sepsis reflects an infection-induced systemic inflam-
matory response syndrome2. Early-onset sepsis (EOS) is most 
commonly differentiated from late-onset sepsis (LOS) by the 
onset occurring before or after the first 72 h of life, respec-
tively3. Of note, both the clinical features and pathophysiology 
of sepsis varies markedly by age, such that adult, pediatric and 
neonatal sepsis criteria are distinct1. While screening and proph-
ylaxis for Group B Streptococcus has reduced rates of EOS 
(i.e., within the first 3 days of life), LOS in the preterm infant 
has increased in frequency as a higher number of premature 
infants have survived, resulting in invasive procedures and pro-
longed hospital stays, as well as increased pathogen exposure3,4. 
LOS considerably lengthens the infant’s hospital stay, and 
is associated with long-term neurodevelopmental complications 
and a high risk of mortality1. Risk of LOS is inversely 
related to birth weight and gestational age (GA); as such, 
preterm and very low birth weight infants are at a higher risk of 
infection5. Accordingly, there is a need to reduce and mitigate 
neonatal LOS.
One approach to reducing and mitigating LOS in high-risk 
newborns is the use of immunomodulatory strategies. Among 
these, a promising area for investigation are antimicrobial 
proteins and peptides (APPs)6. For example, administration of 
oral lactoferrin to preterm newborns reduces the risk of sepsis 
and necrotizing enterocolitis7. In the present study we focused 
on the potential utility of two APPs with distinct modes of 
action: (a) the α-helical LL-37 cationic cathelicidin8 is a broad 
spectrum membrane-active antimicrobial peptide that induces 
microbial lysis, blocks endotoxin activity, synergizes with other 
host defense systems,9 and modulates inflammatory responses9,10; 
and (b) mannose-binding lectin (MBL), a host pattern recog-
nition receptor that recognizes and binds to sugar moieties 
on the surface of bacteria and fungi, enhances opsonophago-
cytosis, and forms complexes with MBL-associated serine 
proteases that trigger complement activation11. Indeed, relatively 
low plasma LL-37 or MBL concentrations are associated with a 
higher risk of infection9,12. Deficiencies in LL-37 or MBL 
levels can be genotypic13,14, such as genetic variants of exon 1 on 
the human MBL gene (MBL2), or phenotypic such as reduced 
expression of APPs in preterm plasma15,16. Some premature 
infants have a distinct immune system, and some may be 
MBL-deficient, as defined in prior neonatal studies by plasma/
serum concentrations <700 ng/ml11,17. Accordingly, it has been 
hypothesized that the administration of recombinant MBL (rMBL) 
as a supplement to bolster the neonatal innate immune system 
could reduce the risk of LOS11. However, to our knowledge, no 
published studies have examined addition of rMBL to human 
newborn blood.
To characterize the activity of LL-37 and rMBL in neonatal 
blood, we evaluated antimicrobial activity towards three 
pathogens commonly associated with LOS in newborns: 
(a) Staphylococcus epidermidis (SE), that accounts for 78% 
of cases of LOS due to coagulase-negative staphylococci, 
(b) Staphylococcus aureus (SA), a less common pathogen 
associated with a high rate of mortality; and Candida albicans 
(CA) the most common fungal pathogen associated with LOS. 
We also conducted a sub-analysis with respect to rMBL effects 
in term cord blood with low baseline levels vs those with high 
baseline MBL levels. We found that these agents exerted dis-
tinct antimicrobial activity that depended on both pathogen 
and age. Specifically, rMBL demonstrated modest fungistatic 
activity vs CA in term newborns with high basal MBL levels. 
By contrast, LL-37 demonstrated substantial antimicrobial 
activity that was generally greater in term (SA, SE and CA) 
than in preterm (SE and CA) blood tested in vitro. The 
antimicrobial activity of rMBL and LL-37 in vitro depends 
on three factors: the baseline endogenous level of APP, 
the pathogen identity and the age of the host, informing the 
translational development of these promising agents.
Methods
APPs
rMBL, provided by Shire (Lexington, MA), was expressed 
in HEK293 cells and purified by affinity chromatography on 
Glucosamine Sepharose 4FF and ion exchange chromatog-
raphy on Source 30Q and diafiltration (100 kDa) from GE 
Healthcare Life Sciences (Pittsburg, PA, USA), including a 
Benzonase DNA removal step from MilliporeSigma (Billerica, 
MA) or similar and several microfiltration and nanofiltration 
steps for bioburden and adventitious virus elimination. rMBL 
was provided frozen, aliquoted at 10× assay concentration, 
and stored in single-use quantities to minimize freeze-thaw. 
LL-37 was purchased from AnaSpec, Inc. (Fremont, California); 
it was purchased in 1 mg vials, re-suspended in 1 ml distilled 
water and frozen in aliquots (stock concentration 1 mg/ml) 
at -80°C.
Microbial pathogens
The anti-infective effect of rMBL and LL-37 was assessed in 
three pathogens: (a) SE strain 1457, a clinical isolate from a 
central catheter infection (kindly provided by Dr. Michael Otto, 
National Institute of Allergy & Infectious Diseases, National 
Institutes of Health, Rockville, MD), was cultured in tryp-
ticase soy broth (TSB), as previously described18; (b) SA 
strain USA300, a strain of community-associated methicillin- 
resistant SA (kindly provided by Dr. William Nauseef, Univer-
sity of Iowa; Iowa City, IA) that was cultured in TSB; and (c) CA 
strain SC531419, (kindly provided by Dr. Julia Koehler, Division 
of Infectious Diseases, Boston Children’s Hospital, Boston, MA), 
which was cultured in yeast extract-peptone-dextrose (YPD) 
broth.
Cord blood collection
Cord blood was obtained from 30 human newborns: 22 term 
newborns ranging from 37 0/7 to 40 4/7 weeks GA and 8 preterm 
newborns ranging from 26 1/7 to 36 6/7 weeks GA. Cord blood 
samples were collected at The Brigham and Women’s Hospital 
(BWH) and Beth Israel Deaconess Medical Center (BI), both 
tertiary care centers for newborn delivery and postnatal care. 
De-identified newborn cord blood was collected immediately 
after Caesarian section or vaginal delivery of the placenta from 
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a large umbilical vein and was anti-coagulated with pyrogen-
free hirudin (Verum Diagnostica GmbH, Munich, Germany). 
Since the mechanism of action of MBL involves complement 
activation, we used Hirudin as an anticoagulant which does not 
impact complement activation. We did not use Heparin or EDTA 
as coagulants, as Heparin, is known to bind to complement 
and EDTA may inhibit complement activation. Inclusion 
criteria were either term or preterm gestational age; and birth 
via vaginal delivery or caesarian section. Sample collections 
included both male and female newborns. Exclusion criteria 
were maternal fever peripartum (>104°F/40°C) or seropositive 
status for human immunodeficiency virus.
Patient information concerning the collected cord blood sam-
ples was collected in a de-identified manner and hence maternal 
consent was waived by the local institutional review boards at 
The Brigham and Women’s Hospital (Protocol #:2000P000117/
BWH) and the Beth Israel Deaconess Medical Center (Protocol 
#2011P-000118/BIDMC. The data associated with our study 
has been provided in an Excel-compatible format.
Assay protocol
A total of 10–20 ml of term or preterm cord blood was 
collected in hirudin vacutainers at room temperature and proc-
essed within 4 h of collection. A total of 1 ml hirudinated blood 
was centrifuged and plasma collected and cryopreserved at -80°C 
for subsequent evaluation of MBL concentrations via ELISA 
(Hycult®biotech; Cat. No. HK323-01). Endogenous LL-37 levels 
were not determined. LL-37 was prepared at 10× assay con-
centration in 1× saline. A total of 15 µl negative control 
(saline), rMBL (500 ng/ml, 2000 ng/ml, or 10,000 ng/ml), or 
LL-37 reagents (1 mg of protein/ml) as well as 15 µl SA strain 
USA300 (2×104/ml), SE strain 1457 (2×104/ml) or CA (final 
concentration 1×104 CFU/ml) in saline were added to 120 µl 
hirudin-anticoagulated preterm and term human cord blood 
and incubated at 37°C. At 1, 45, and 180 min, 10–20 µl of each 
replicate was spread on tryptic soy blood agar plates to quan-
tify colony forming units (CFUs). Plate CFUs were counted 
16–18 h after assay commencement for SA and SE, or at 48 h 
after assay commencement for CA using the Accu Count™ 
1000, Automated Colony Counter (BioLogics, Inc.). This 
automated colony counter was carefully calibrated, and the assay 
designed to ensure colony counts <200 colonies per plate in 
order to facilitate reliable colony counts. Of note, the cord blood 
collection volumes obtained permitted incubation with all three 
pathogens in 20 of the term patient samples, incubation with SA 
and SE but not CA in one term sample, and incubation with 
SA only in one term sample.
Statistical analyses and graphics
Data were analyzed and graphed using Prism for MacIntosh 
v. 7.0 (GraphPad Software, Inc.). Tests used for statistical 
comparisons are indicated in the figure legends. P values <0.05 
were considered significant. Statistical analysis was performed 
via two-way ANOVA with either a Sidak’s post hoc test (Figure 1, 
Figure 2 panels (B) and (C), Figure 3 panel (C), Figure 4 panel 
(C) and Figure 5 panel (C) or Dunnett’s post hoc test (Figure 3 
panels (A) and (B), Figure 4 panels (A) and (B), and Figure 5 
panels (A) and (B). In Figure 2 panel (A), Spearman’s correlation 
was performed.
Figure 1. Preterm cord blood exhibits a lower killing capacity against S. epidermidis (A) and S. aureus (B) than term cord blood at 180 min. 
While the trend towards lower killing activity by preterm cord blood was observed for C. albicans (C) at 45 min, the difference did not reach 
statistical significance. Killing capacity was measured at 1 min, 45 min and 180 min; the inoculum (SA and SE, 2x104 CFU/ml; CA, 1x104/ml) 
at time-point “0” is plotted at “0.1 min”. CFU counts are expressed in percent of CFUs detected at 1 min. Term, N = 20–22 (N = 20 for CA; N 
= 21 for SE; N = 22 for SA); preterm, N = 8. Statistical analysis was performed via two-way ANOVA with Sidak’s post hoc test. ****p<0.0001. 
**p<0.005. All graphs depict mean and error with SEM.
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Figure 2. Exogenous MBL in term cord blood with high baseline MBL levels exerts modest antimicrobial activity towards C. albicans 
(CA) but not S. epidermidis (SE). (A) Scattergram of plasma MBL levels as a function of gestational age. Baseline MBL levels that do not 
correlate with gestational age. (B) No statistical significance in the antimicrobial effect against SE between MBL treatment vs saline in the low 
or high baseline MBL groups when analyzed separately. (C) Enhanced antifungal effect of exogenous MBL towards CA in term newborns with 
high baseline MBL levels only. Statistical analysis was performed in panels (B) and (C) via repeated measure two-way ANOVA with Sidak’s 
post hoc test. ***p<0.005. All graphs depict mean and error with SEM. CFU counts was measured at 1 min, 45 min and 180 min, the inoculum 
(SA and SE, 2x104 CFU/ml; CA, 1x104 CFU/ml) at time-point “0” is plotted at “0.1 min”. A Spearman correlation was performed for panel (A), 
which demonstrates no correlation between gestational age and baseline MBL levels in our cohort (r=0.1834, p=0.3319). CFU counts in (B) 
and (C) are expressed in percent of CFUs detected in saline treated control blood obtained from the same individual at 1 min. (A) Baseline 
MBL levels detected in a total of 30 samples (22 term, 8 preterm); (B) SE: Low baseline MBL N = 6; High baseline MBL N = 15; (C) CA: Low 
baseline MBL N = 5; High baseline MBL N = 15.
Figure 3. LL-37 significantly inhibits growth of S. aureus in term but not preterm cord blood relative to saline control at 180 min. 
Viability of SA as measured in CFU is plotted on the y-axis relative to the incubation time in panels (A) and (B). (A) Neither LL-37 nor MBL 
inhibit growth of SA in preterm blood. (B) LL-37 significantly inhibits SA growth in term blood at 180 min. (C) Summary of LL-37 effects on 
SA growth in term and preterm cord blood at 180 min, demonstrating that the inhibitory effect of LL-37 is more pronounced in term than 
in preterm cord blood. The inoculum (2×104 CFU/ml) at time-point “0” is plotted at 0.1 min. Term, N = 20–22; preterm, N = 8. **p<0.005. 
Statistical analysis employed two-way ANOVA with Dunnett’s (A, B) or Sidak’s (C) post hoc test. All graphs depict mean and error with SEM.
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Figure 5. LL-37, but not MBL, demonstrates antimicrobial activity towards C. albicans in preterm and term cord blood relative to 
saline control. Viability of CA as measured in CFU is plotted on the y-axis relative to the incubation time in panels (A) and (B). (A) LL-37 but 
not MBL inhibits growth of CA in preterm blood at 1 min, 45 min and 180 min. (B) Significant LL-37 inhibition of SE growth in term blood at 1 
min, 45 min and at 180 min. (C) Summary of LL-37 effects on SE growth in term and preterm cord blood at 180 min, demonstrating an equally 
pronounced inhibitory effect of LL-37 on CA growth in term and preterm cord blood. The inoculum (1x104 CFU/ml) at time-point “0” is plotted 
at 0.1 min. Term N = 20; preterm N = 8. Statistical analysis employed two-way ANOVA with Dunnett’s (A, B) or Sidak’s (C) post hoc test. 
**** p<0.0005. All graphs depict mean and error with SEM. 
Figure 4. LL-37, but not MBL, exhibits antibacterial activity towards S. epidermidis (SE) in human preterm and term cord blood 
relative to saline control. Viability of SE as measured in CFU is plotted on the y-axis relative to the incubation time in panels (A) and (B). 
(A) LL-37 but not MBL inhibits growth of SE in preterm blood at 45 min and 180 min. (B) LL-37 significantly inhibits SE growth in term blood 
at 1 min, 45 min and 180 min. (C) Summary of LL-37 effects on SE growth in term and preterm cord blood at 180 min, demonstrating that the 
inhibitory effect of LL-37 is stronger in term than in preterm cord blood. The inoculum (2x104 CFU/ml) at time-point “0” is plotted at 0.1 min. 
Term N = 21–22 (N = 20 for CA; N = 21 for SE; N = 22 for SA); preterm N = 8. Statistical analyses employed two-way ANOVA with Dunnett’s 
(A, B) or Sidak’s (C) post hoc test. *p<0.05, ***p<0.0005, ****p<0.0005. All graphs depict mean and error ± SEM.
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Results
Preterm cord blood demonstrates lesser killing activity 
against SA and SE than term cord blood
Overall, bacterial viability decreased over time in our whole-
blood assay (Figure 1). In accordance with the known defi-
ciency of antimicrobial mechanisms in preterm infants, preterm 
cord blood demonstrated significantly lower killing capacity 
against SE (Figure 1A) or SA (Figure 1B) than term cord 
blood at 180 min. The viability of CA increased modestly 
over time in both preterm and term cord blood, with no 
significant differences observed between age groups (Figure 1C).
Exogenous rMBL in term cord blood exerts modest 
antimicrobial activity towards CA in term cord blood with 
high basal MBL levels. Basal MBL levels did not appear to 
be GA-dependent
Individuals were stratified into high vs low baseline plasma 
MBL values, using a threshold of 700 ng/ml, in keeping with 
past studies11. Baseline MBL concentrations within both preterm 
and term groups varied broadly (Figure 2A). GA and base-
line MBL level were not significantly correlated (Spearman 
r = 0.18, p = 0.33). This suggests that MBL concentrations 
did not vary by GA, in agreement with the results of other 
groups20. In our term cohort, exogenous rMBL, when added to 
high baseline MBL cord blood, showed a modest fungistatic 
effect against CA when compared with saline treated control 
high baseline MBL term cord blood at 180 min (Figure 2C). 
By contrast, exogenous rMBL demonstrated no bactericidal 
effect against SE in low or high baseline MBL term cord blood 
(Figure 2B). With respect to SA, there was no significant 
effect of high-dose rMBL addition to term cord blood with 
low or high baseline MBL levels (data not shown).
LL-37, but not rMBL, significantly inhibits growth of SA in 
term, but not preterm, cord blood
Figure 3 demonstrates the effects of addition of LL-37 as well 
as rMBL at three different concentrations on the growth of SA 
in preterm and term cord blood. In preterm cord blood, the 
addition of neither rMBL nor LL-37 inhibited the growth of SA 
relative to the saline control (Figure 3A). By contrast, in term 
cord blood, LL-37 significantly decreased SA growth at 180 
min, whereas rMBL did not (Figure 3B). The inhibitory effect 
of LL-37 on SA growth was more pronounced in term cord 
blood than in preterm cord blood (Figure 3C).
LL-37, but not rMBL, exhibits antibacterial activity towards 
S. epidermidis in human preterm and term cord blood
As demonstrated in Figure 4, LL-37 demonstrated a pronounced 
inhibitory effect on SE growth in both preterm (Figure 4A) 
and term cord blood (Figure 4B) at 45 and 180 min. In 
term cord blood this effect was evident at 1 min incubation. 
rMBL showed no bactericidal effect against SE in preterm 
(Figure 4A) or term (Figure 4B) cord blood. When comparing 
the bactericidal effect of LL-37 at 180 min in term cord blood 
to preterm cord blood, the effect in term cord blood was more 
pronounced (Figure 4C).
LL-37, but not rMBL, demonstrates antimicrobial activity 
towards CA in preterm and term cord blood relative to 
saline control
Figure 5 demonstrates the significant growth inhibitory effect 
of LL-37 on CA growth in preterm (Figure 5A) and term cord 
blood (Figure 5B) relative to saline control at all three time 
points measured. rMBL demonstrated no inhibitory effect on 
CA growth in preterm or term cord blood. The inhibitory effect 
of LL-37 on growth of CA at 180 min was as significant in 
preterm cord blood as it was in term cord blood (Figure 5C).
Dataset 1. The complete raw data for the study, organized per 
figure
http://dx.doi.org/10.5256/f1000research.14736.d20331721 
Discussion
In this study we have, to our knowledge for the first time, 
characterized the antimicrobial activity of exogenous LL-37 
and rMBL when added to human preterm and term cord blood 
in vitro. While some studies suggest that relatively low serum 
MBL or LL-37 levels are associated with a risk of specific 
infections9,12,22–25, to our knowledge, including PubMed search 
as of date 2/24/18 using the term “LL-37” and “cord blood”, or 
“mannose binding lectin” and “cord blood”, none have measured 
the activity of these APPs when added to preterm or term 
newborn blood.
Of note, preterm cord blood demonstrated a lower killing 
capacity against SA and SE than term cord blood. To our knowl-
edge, this has not been demonstrated previously. As killing may 
be both extracellular and/or intracellular, this impairment in 
killing may reflect known deficits in plasma APP content with 
GA16 and/or impaired preterm neutrophil function, such as 
reduced chemotaxis and chemokinesis26.
In our cohort of newborns, MBL levels were markedly variable 
among both preterm and term cord blood samples and thus 
did not seem to correlate with GA (Figure 2A), consistent 
with studies demonstrating that cord blood MBL levels most 
closely reflect MBL genotype distribution rather than GA20.
In our study, MBL, at the concentrations tested in hirudinated 
whole blood, did not inhibit growth of SA, SE or CA in term or 
preterm cord blood. MBL in a sub-analysis of basal MBL levels, 
did exert modest fungistatic activity against CA in term 
newborn blood.
LL-37 demonstrated significant antimicrobial and antifungal 
activity towards SE, SA and CA in term cord blood. It also 
demonstrated strong antimicrobial effects against SE and anti-
fungal effects against CA in preterm cord blood. LL-37 generally 
exerted lesser antibacterial activity in preterm than in term 
blood, suggesting that it may act together with other host 
defense components that increase with GA. Of note, amongst 
other APPs, LL-37 levels are expressed in human breast milk, 
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which demonstrated bacterial growth inhibitory effects towards 
both SA and SE, with activity towards SE increasing with the 
postnatal age of the breast milk expression27. LL-37 has previ-
ously been demonstrated to be a potent antimicrobial in adult 
peripheral blood28.
Our study featured several strengths, including the use of a 
species- and GA-specific human whole blood assay system that 
is: (a) relatively physiological, (b) has been predictive of APP 
activity in vivo29, and (c) enables blood samples from the same 
individual to be assayed in both control and treatment condi-
tions, including testing across a time range to characterize kinetic 
effects, thereby enhancing statistical power via paired analyses. 
Our study also has several limitations including: (a) relatively 
greater number of cord blood samples from term study participants 
(N = 22) than from preterm participants (N = 8), limiting 
the power to detect age-specific differences; (b) an absence 
of measurement of endogenous LL-37 levels due to sam-
ple and logistical limitations; and (c) limitations of the whole 
blood assay which, although it is often predictive, does not 
perfectly model in vivo conditions, including blood flow and 
endothelial interactions.
In conclusion, rMBL exhibited very modest fungistatic proper-
ties when added to term cord blood with high baseline MBL lev-
els. By contrast, LL-37 inhibited the growth of SA, SE and CA 
in term cord blood, and SE and CA in preterm cord blood. To 
the extent that our in vitro system is relevant in vivo, LL-37 and 
its congeners30, such as immunoglobulin-based constructs that 
enhance half-life, may be promising agents to prevent and/or 
treat neonatal sepsis. Further translational studies of LL-37 
designed to take into account both the pathogen identity and GA 
of the target population are warranted.
Data availability
Dataset 1. The complete raw data for the study, organized per 
figure. DOI: 10.5256/f1000research.14736.d20331721.
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